Eagle Pharmaceuticals (NASDAQ: EGRX) is one of 19 public companies in the “Specialty & Advanced Pharmaceuticals” industry, but how does it contrast to its peers? We will compare Eagle Pharmaceuticals to related businesses based on the strength of its earnings, profitability, institutional ownership, risk, analyst recommendations, valuation and dividends.
This table compares Eagle Pharmaceuticals and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Eagle Pharmaceuticals Competitors||-538.85%||-41.85%||-24.81%|
Insider and Institutional Ownership
66.4% of shares of all “Specialty & Advanced Pharmaceuticals” companies are owned by institutional investors. 19.5% of Eagle Pharmaceuticals shares are owned by insiders. Comparatively, 10.0% of shares of all “Specialty & Advanced Pharmaceuticals” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
This is a summary of current ratings and recommmendations for Eagle Pharmaceuticals and its peers, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Eagle Pharmaceuticals Competitors||98||370||970||28||2.63|
Eagle Pharmaceuticals presently has a consensus target price of $72.50, suggesting a potential upside of 25.82%. As a group, “Specialty & Advanced Pharmaceuticals” companies have a potential upside of 22.13%. Given Eagle Pharmaceuticals’ higher probable upside, equities analysts clearly believe Eagle Pharmaceuticals is more favorable than its peers.
Volatility and Risk
Eagle Pharmaceuticals has a beta of 1.3, indicating that its share price is 30% more volatile than the S&P 500. Comparatively, Eagle Pharmaceuticals’ peers have a beta of 0.81, indicating that their average share price is 19% less volatile than the S&P 500.
Valuation & Earnings
This table compares Eagle Pharmaceuticals and its peers top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Eagle Pharmaceuticals||$245.88 million||$83.99 million||9.68|
|Eagle Pharmaceuticals Competitors||$2.57 billion||$977.16 million||2.89|
Eagle Pharmaceuticals’ peers have higher revenue and earnings than Eagle Pharmaceuticals. Eagle Pharmaceuticals is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
Eagle Pharmaceuticals beats its peers on 8 of the 13 factors compared.
Eagle Pharmaceuticals Company Profile
Eagle Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company focuses on developing and commercializing injectable products in the critical care and oncology areas. The Company’s product portfolio includes products, including Argatroban; Ryanodex; docetaxel injection, non-alcohol formulation; and Bendeka. Its advanced candidates include EP-3101 (bendamustine Resistance Temperature Detectors (RTD)) (EP-3101), EP-4104 (dantrolene sodium for exertional heat stroke (EHS)) (EP-4104), EGL-4104-C-1702 (dantrolene sodium for drug induced hyperthermia), EP-5101 (pemetrexed) (EP-5101) and EGL-5385-C-1701 (fulvestrant). Its product portfolio focuses on oncology, critical care and orphan diseases. Bendamustine is an alkylating agent approved for use in chronic lymphocytic leukemia (CLL), and indolent B-cell non-Hodgkin’s lymphoma (NHL), that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.
Receive News & Ratings for Eagle Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.